Speaking to Express.co.uk, the campaign group said: “There is strong clinical support for Evusheld across a range of medical specialties. Nonetheless, we are concerned that Evusheld is being held to an impossible standard of evolving evidence.
“Despite real-world studies showing strong performance against Omicron BA1 and BA2, and subsequent data for BA4 and BA5, there has been a lack of transparency relating to government testing and how this will influence procurement and roll-out. We have also seen requests for studies on specific patient sub-groups, delaying administration even further.”
They argue Evusheld would not only free people but also help the NHS and improve the economy: “Further, the economic benefits of Evusheld outweigh the costs. Our vulnerable members are currently extremely limited in their ability to participate in society. For many, the first lockdown of 2020 has never ended.
“A drug that could significantly reduce the risk of poor outcomes from Covid would have far-reaching benefits for the economy. The fact that Evusheld substantially reduces hospitalisation in this group would also have a positive impact on NHS bed space.”